Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ankle replacement

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Ankle replacement. Displaying page 1 of 1.
    EudraCT Number: 2016-000608-27 Sponsor Protocol Number: ProtokolSB2 Start Date*: 2016-04-05
    Sponsor Name:Aarhus University Hospital
    Full Title: The effect of subsartorial saphenous block on postoperative pain following major ankle and hind foot surgery
    Medical condition: Post-operative pain after four types of major ankle and hind foot surgery: (1) total ankle arthroplasty, (2) ankle arthrodesis, (3) subtalar arthrodesis or (4) triple arthrodesis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10003396 Arthroplasty NOS LLT
    19.0 100000004865 10016962 Foot arthrodesis LLT
    19.0 100000004865 10002540 Ankle arthrodesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-004207-78 Sponsor Protocol Number: ProtokolSB1 Start Date*: 2015-01-07
    Sponsor Name:Aarhus University Hospital
    Full Title: Comparison of the effect of saphenous block with plain bupivacaine vs. protracted bupivacaine mixture as a supplement to continuos sciatic catheter after major ankle and foot surgery: a randomized ...
    Medical condition: Post-operative pain after three types of major ankle and hind foot surgery: (1) total ankle arthroplasty, (2) ankle arthrodesis or (3) subtalar arthrodesis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004865 10003396 Arthroplasty NOS LLT
    17.1 100000004865 10016962 Foot arthrodesis LLT
    17.1 100000004865 10002540 Ankle arthrodesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003652-35 Sponsor Protocol Number: 300 Start Date*: 2006-02-02
    Sponsor Name:Barnsley Hospital NHS Foundation Trust
    Full Title: A randomised, double blind, placebo controlled study to assess the effect of testosterone treatment on arterial stiffness in patients with type 2 diabetes, peripheral vascular disease and hypogonad...
    Medical condition: Male Hypogonadism
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001644-35 Sponsor Protocol Number: CR_TFB_2017 Start Date*: 2017-06-01
    Sponsor Name:Aarhus University Hospital
    Full Title: The effect of popliteal plexus block on pain after total knee replacement
    Medical condition: In this study we investigate pain after total knee replacement
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10038286 Regional nerve block LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-000242-17 Sponsor Protocol Number: Protocol_PPB_TKA_14012021 Start Date*: 2021-03-12
    Sponsor Name:Region Hospital Silkeborg
    Full Title: The effect of the popliteal plexus block on postoperative opioid consumption, pain, muscle strength and mobilization after total knee arthroplasty - a randomized, controlled, blinded study
    Medical condition: Postoperative pain following a total knee arthroplasty surgery
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10036236 Postoperative pain relief LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2017-005180-40 Sponsor Protocol Number: Protocol_PPB_TKA_31122017 Start Date*: 2018-02-19
    Sponsor Name:Aarhus University Hospital
    Full Title: The effect of the popliteal plexus block on postoperative pain after total knee arthroplasty - a randomized, controlled, double-blinded study
    Medical condition: Postoperative posterior pain after total knee arthroplasty
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10023469 Knee arthroplasty PT
    20.0 10042613 - Surgical and medical procedures 10002325 Anesthesia local LLT
    20.0 10042613 - Surgical and medical procedures 10036236 Postoperative pain relief LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-000822-58 Sponsor Protocol Number: C9253 Start Date*: 2004-07-13
    Sponsor Name:Sanofi-Synthelabo Groupe
    Full Title: A double blind randomized study of Clopidogrel 75 mg/d versus placebo on a background of ASA 75-100 mg/d, in peripheral disease (PAD) patient receiving a unilateral below knee by-pass graft.
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    7.0 10062585 1
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) HU (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-004563-31 Sponsor Protocol Number: Au18-12 Start Date*: 2022-07-25
    Sponsor Name:Centre Hospitalier Universitaire de Reims
    Full Title: Cell therapy in Critical Limb Ischemia by implantation of allogeneic umbilical cord-derived mesenchymal stem cells
    Medical condition: Evaluation of the feasibility and systemic and local tolerance of an implantation, via intramuscular route, of allogenic HB-MSC1, associated with a revascularization procedure, in patients sufferin...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004853-59 Sponsor Protocol Number: EX6018-4758 Start Date*: 2021-08-16
    Sponsor Name:Novo Nordisk A/S
    Full Title: ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation
    Medical condition: Atherosclerotic cardiovascular disease Chronic kidney disease Systemic inflammation
    Disease: Version SOC Term Classification Code Term Level
    26.0 10047065 - Vascular disorders 10051615 Atherosclerotic cardiovascular disease LLT
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.1 10022891 - Investigations 10067394 hs-CRP increased LLT
    21.0 10022891 - Investigations 10011418 CRP increased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Trial now transitioned) SK (Trial now transitioned) DE (Trial now transitioned) NL (Ongoing) SE (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) BG (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) HU (Trial now transitioned) CZ (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003141-42 Sponsor Protocol Number: EX9924-4473 Start Date*: 2019-07-03
    Sponsor Name:Novo Nordisk A/S
    Full Title: Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) NL (Completed) GB (GB - no longer in EU/EEA) SK (Completed) DE (Completed) BE (Completed) AT (Completed) ES (Ongoing) CZ (Completed) FR (Completed) HR (Completed) IT (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001824-32 Sponsor Protocol Number: 116174 Start Date*: 2015-03-05
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A long term, randomised, double blind, placebo-controlled study to determine the effect of albiglutide, when added to standard blood glucose lowering therapies, on major cardiovascular events in pa...
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) CZ (Completed) GB (Completed) SE (Completed) NL (Completed) HU (Completed) BE (Completed) DK (Completed) ES (Completed) BG (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005855-35 Sponsor Protocol Number: U1111-1270-0943 Start Date*: 2023-01-10
    Sponsor Name:NOVO NORDISK. S.P.A.
    Full Title: The cardiovascular safety of cagrilintide 2.4 mg s.c. in combination with semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) once-weekly in participants with obesity and established cardiovascu...
    Medical condition: Atherosclerotic cardiovascular disease and Obesity
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) IE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) NL (Trial now transitioned) BG (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000091-40 Sponsor Protocol Number: RS03-2004 Start Date*: 2005-11-08
    Sponsor Name:ApoPharma Inc.
    Full Title: Pivotal Study to Evaluate the Efficacy and Safety of Dermal - Living Skin Replacement (Dermal – LSR) in the Treatment of Chronic Diabetic Foot Ulcers
    Medical condition: Chronic Diabetic Foot Ulcers
    Disease: Version SOC Term Classification Code Term Level
    9.0 10012664 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023799-21 Sponsor Protocol Number: H9X-MC-GBDJ Start Date*: 2011-10-06
    Sponsor Name:Eli Lilly & Company
    Full Title: The Effect of Dulaglutide on Major Cardiovascular Events in Patients with Type 2 Diabetes: Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND)
    Medical condition: Cardiovascular events in patients with Type 2 diabetes
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004860 10012654 Diabetic complications cardiovascular HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) LV (Completed) CZ (Completed) HU (Completed) GB (Completed) PL (Completed) ES (Completed) BG (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-001249-41 Sponsor Protocol Number: KEK-ZH-2012-0249 Start Date*: 2013-04-12
    Sponsor Name:University Hospital of Zurich and City Hospital Waid
    Full Title: Vitamin D3 – Omega3 – Home Exercise – HeALTHy Ageing and Longevity Trial Randomized, double-blind, placebo-controlled, multi-centre clinical trial
    Medical condition: healthy ageing, functional decline
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) PT (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000407-16 Sponsor Protocol Number: 2197944/202 Start Date*: 2013-07-24
    Sponsor Name:Convergence Pharmaceuticals Ltd
    Full Title: A randomised three week double-blind crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in the treatment of neuropathic pain in patients with diabetic periphe...
    Medical condition: Neuropathic pain associated with diabetic peripheral neuropathy
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004852 10067547 Diabetic peripheral neuropathic pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) BG (Completed) PL (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2022-000889-18 Sponsor Protocol Number: DYNE101-DM1-201 Start Date*: 2023-02-08
    Sponsor Name:Dyne Therapeutics
    Full Title: A Randomized, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-101 Administered to Participants with Myoton...
    Medical condition: Myotonic Dystrophy Type 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068871 Myotonic dystrophy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016178-33 Sponsor Protocol Number: 1245.25 Start Date*: 2010-11-12
    Sponsor Name:Boehringer Ingelheim B.V.
    Full Title: A Phase III, multicentre, international, randomised, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in ...
    Medical condition: The study will be performed in patients with type 2 diabetes mellitus and high cardiovascular risk who have insufficient glycaemic control despite diet and exercise and are either treatment naïve o...
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) ES (Completed) BE (Completed) FR (Completed) IT (Completed) HU (Completed) PT (Completed) GB (Completed) AT (Completed) GR (Completed) PL (Completed) EE (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 13:08:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA